# UPB — Upstream Bio Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** UPB  
**Sources:** 16  
**Published:** 2026-10-31  
**Canonical:** https://app.k3vl4r.com/research/deep-research-upb-upstream-bio-inc-catalysts-narrative-risks-10380

---

## Upstream Bio, Inc. (NASDAQ: UPB) — as of 2026-10-31

Upstream Bio is a clinical-stage biotech headquartered in Waltham, Massachusetts, with a single clinical asset, **verekitug**, an investigational long-acting monoclonal antibody targeting the thymic stromal lymphopoietin (TSLP) receptor. As of the Oct. 30, 2026 close, the stock traded near **$3.41** with a market capitalization of roughly **$187 million**, down about **87% year-to-date** and roughly **90% from its January 2026 52-week high of $33.68** [[2]](https://tickeron.com/blogs/upstream-bio-upb-stock-slides-48-over-30-days-phase-2-data-and-funding-concerns-weigh-in-22828/), [[11]](https://tickernerd.com/stock/upb-forecast/), [[16]](https://stockanalysis.com/stocks/upb/), [[17]](https://stockanalysis.com/stocks/upb/market-cap/).

---

## Recent Catalysts (approx. July–October 2026)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-upb-upstream-bio-inc-catalysts-narrative-risks-10380 (free to sign up)._